Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Toshihiko Masui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4001-4824; OpenAlex author ID A5003456073, A5070175112. Sources: OpenAlex.

Their work

Papers
27 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 27

  1. Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective S… Co-author DOI 10.1097/sla.0000000000007052↗
  2. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci206371↗
  3. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Co-author DOI 10.1007/s00066-025-02433-9↗
  4. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci177533↗
  5. Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Ret… Co-author DOI 10.1245/s10434-025-16956-z↗
  6. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.09.002↗
  7. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Co-author DOI 10.1002/cam4.6470↗
  8. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… Co-author DOI 10.1007/s12032-023-02011-y↗
  9. Association between patient's age and the utility of prognostic markers after pancreaticoduodenectomy for pancreatic cancer. First author DOI 10.1016/j.asjsur.2022.10.009↗
  10. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Co-author DOI 10.1038/s41388-023-02716-4↗
  11. Preoperative Endoscopic Minor Papilla Sphincterotomy for Pancreas Divisum in a Patient with Pancreatic Cancer Who Underwent Laparoscopic Distal Pancreatectomy. First author DOI 10.1245/s10434-023-13975-6↗
  12. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Co-author DOI 10.1186/s12885-022-09244-6↗
  13. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. Co-author DOI 10.1186/s12885-022-09619-9↗
  14. A Case of Misdiagnosed Pancreatic Cancer With Concomitant Type 1 Autoimmune Pancreatitis. Last author DOI 10.1097/mpa.0000000000001727↗
  15. SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. Co-author DOI 10.1111/cas.15162↗
  16. Left-posterior approach for artery-first en bloc resection in laparoscopic distal pancreatectomy for left-sided pancreatic cancer. Last author DOI 10.1007/s00423-020-02021-8↗
  17. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective… First author DOI 10.1016/j.suronc.2020.10.010↗
  18. Time-frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer. First author DOI 10.1038/s41598-020-79087-3↗
  19. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/s13014-018-1063-5↗
  20. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24865↗
  21. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. Co-author DOI 10.1097/md.0000000000009217↗
  22. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Co-author DOI 10.21873/anticanres.12172↗
  23. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Co-author DOI 10.1007/s00595-016-1310-z↗
  24. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
  25. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.02.002↗
  26. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report. Co-author DOI 10.1186/1477-7819-11-195↗
  27. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00280-010-1470-2↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Etsuro Hatano · 12 shared papers, 2022–2026 · strength 2.11
  2. Kazuyuki Nagai · 10 shared papers, 2020–2026 · strength 1.67
  3. Akihisa Fukuda · 9 shared papers, 2021–2026 · strength 1.52
  4. Hiroshi Seno · 7 shared papers, 2017–2026 · strength 1.05
  5. Shinji Üemoto · 10 shared papers, 2015–2023 · strength 0.99
  6. Michio Yoshimura · 6 shared papers, 2020–2025 · strength 0.94
  7. Masashi Kanai · 9 shared papers, 2011–2025 · strength 0.88
  8. Kei Yamane · 4 shared papers, 2023–2026 · strength 0.81
  9. Asahi Sato · 6 shared papers, 2016–2026 · strength 0.75
  10. Takahisa Maruno · 4 shared papers, 2023–2026 · strength 0.70
  11. Makoto Sono · 4 shared papers, 2023–2026 · strength 0.70
  12. Kyoichi Takaori · 9 shared papers, 2015–2022 · strength 0.69
  13. Yuichiro Uchida · 5 shared papers, 2017–2026 · strength 0.68
  14. Takashi Mizowaki · 5 shared papers, 2018–2025 · strength 0.66
  15. Kei Iimori · 3 shared papers, 2024–2026 · strength 0.56
  16. Osamu Araki · 3 shared papers, 2023–2026 · strength 0.53
  17. Motoyuki Tsuda · 3 shared papers, 2023–2026 · strength 0.53
  18. Dieter Saur · 3 shared papers, 2023–2026 · strength 0.53
  19. Takahiro Iwai · 2 shared papers, 2025 · strength 0.42
  20. Munenori Kawai · 2 shared papers, 2025–2026 · strength 0.39
  21. Satoshi Ogawa · 2 shared papers, 2024–2026 · strength 0.38
  22. Junichi Matsubara · 2 shared papers, 2023–2025 · strength 0.34
  23. Shintaro Yagi · 2 shared papers, 2020–2026 · strength 0.32
  24. Takashi Ito · 2 shared papers, 2021–2023 · strength 0.32
  25. Ryo Ashida · 2 shared papers, 2018–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.